Cargando…

Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans

BACKGROUND: Reporting further developments evolved since the first report about this conformal technique. METHODS: Technical progress focused on optimization of the quality assurance (QA) program, especially regarding the required work input; and on optimization of beam arrangements. RESULTS: Beside...

Descripción completa

Detalles Bibliográficos
Autores principales: Wurstbauer, Karl, Deutschmann, Heinz, Kopp, Peter, Merz, Florian, Schöller, Helmut, Sedlmayer, Felix
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731780/
https://www.ncbi.nlm.nih.gov/pubmed/19678961
http://dx.doi.org/10.1186/1748-717X-4-30
_version_ 1782170973178429440
author Wurstbauer, Karl
Deutschmann, Heinz
Kopp, Peter
Merz, Florian
Schöller, Helmut
Sedlmayer, Felix
author_facet Wurstbauer, Karl
Deutschmann, Heinz
Kopp, Peter
Merz, Florian
Schöller, Helmut
Sedlmayer, Felix
author_sort Wurstbauer, Karl
collection PubMed
description BACKGROUND: Reporting further developments evolved since the first report about this conformal technique. METHODS: Technical progress focused on optimization of the quality assurance (QA) program, especially regarding the required work input; and on optimization of beam arrangements. RESULTS: Besides performing the regular QA program, additional time consuming dosimetric measurements and verifications no longer have to be accomplished. 'Class solutions' of treatment plans for six patients with non-resected non-small cell lung cancer in locally advanced stages are presented. Target configurations comprise one central and five peripheral tumor sites with different topographic positions to hilus and mediastinum. The mean dose to the primary tumor is 81,9 Gy (range 79,2–90,0 Gy), to macroscopically involved nodes 61,2 Gy (range 55,8–63,0 Gy), to electively treated nodes 45,0 Gy. Treatments are performed twice daily, with fractional doses of 1,8 Gy at an interval of 11 hours. Median overall treatment time is 33 days. The set-up time at the linac does not exceed the average time for any other patient. CONCLUSION: Target splitting is a highly conformal and nonetheless non-expensive method with regard to linac and staff time. It enables secure accelerated high-dose treatments of patients with NSCLC.
format Text
id pubmed-2731780
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27317802009-08-26 Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans Wurstbauer, Karl Deutschmann, Heinz Kopp, Peter Merz, Florian Schöller, Helmut Sedlmayer, Felix Radiat Oncol Research BACKGROUND: Reporting further developments evolved since the first report about this conformal technique. METHODS: Technical progress focused on optimization of the quality assurance (QA) program, especially regarding the required work input; and on optimization of beam arrangements. RESULTS: Besides performing the regular QA program, additional time consuming dosimetric measurements and verifications no longer have to be accomplished. 'Class solutions' of treatment plans for six patients with non-resected non-small cell lung cancer in locally advanced stages are presented. Target configurations comprise one central and five peripheral tumor sites with different topographic positions to hilus and mediastinum. The mean dose to the primary tumor is 81,9 Gy (range 79,2–90,0 Gy), to macroscopically involved nodes 61,2 Gy (range 55,8–63,0 Gy), to electively treated nodes 45,0 Gy. Treatments are performed twice daily, with fractional doses of 1,8 Gy at an interval of 11 hours. Median overall treatment time is 33 days. The set-up time at the linac does not exceed the average time for any other patient. CONCLUSION: Target splitting is a highly conformal and nonetheless non-expensive method with regard to linac and staff time. It enables secure accelerated high-dose treatments of patients with NSCLC. BioMed Central 2009-08-14 /pmc/articles/PMC2731780/ /pubmed/19678961 http://dx.doi.org/10.1186/1748-717X-4-30 Text en Copyright © 2009 Wurstbauer et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Wurstbauer, Karl
Deutschmann, Heinz
Kopp, Peter
Merz, Florian
Schöller, Helmut
Sedlmayer, Felix
Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans
title Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans
title_full Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans
title_fullStr Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans
title_full_unstemmed Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans
title_short Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans
title_sort target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731780/
https://www.ncbi.nlm.nih.gov/pubmed/19678961
http://dx.doi.org/10.1186/1748-717X-4-30
work_keys_str_mv AT wurstbauerkarl targetsplittinginradiationtherapyforlungcancerfurtherdevelopmentsandexemplarytreatmentplans
AT deutschmannheinz targetsplittinginradiationtherapyforlungcancerfurtherdevelopmentsandexemplarytreatmentplans
AT kopppeter targetsplittinginradiationtherapyforlungcancerfurtherdevelopmentsandexemplarytreatmentplans
AT merzflorian targetsplittinginradiationtherapyforlungcancerfurtherdevelopmentsandexemplarytreatmentplans
AT schollerhelmut targetsplittinginradiationtherapyforlungcancerfurtherdevelopmentsandexemplarytreatmentplans
AT sedlmayerfelix targetsplittinginradiationtherapyforlungcancerfurtherdevelopmentsandexemplarytreatmentplans